
Lane 1: DU145 cell lysates probed with CTAG2 Polyclonal Antibody, Unconjugated (bs-6807R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
CTAG2 Polyclonal Antibody
BS-6807R
ApplicationsWestern Blot, ELISA, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetCTAG2
Overview
- SupplierBioss
- Product NameCTAG2 Polyclonal Antibody
- Delivery Days Customer16
- ApplicationsWestern Blot, ELISA, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- Applications SupplierWB(1:300-5000), ELISA(1:500-1000), IHC-P(1:200-400)
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 ug/ul
- ConjugateUnconjugated
- Gene ID30848
- Target nameCTAG2
- Target descriptioncancer/testis antigen 2
- Target synonymsCAMEL, CT2, CT6.2, CT6.2a, CT6.2b, ESO2, LAGE-1, LAGE2B, cancer/testis antigen 2, CTL-recognized antigen on melanoma, LAGE-1a protein, autoimmunogenic cancer/testis antigen NY-ESO-2, cancer/testis antigen 6.2, cancer/testis antigen family 6, member 2a, cancer/testis antigen family 6, member 2b, l antigen family member 1
- HostRabbit
- IsotypeIgG
- Protein IDO75638
- Protein NameCancer/testis antigen 2
- ReactivityHuman
- Storage Instruction-20°C
- UNSPSC41116161
References
- Identification of cancer/testis antigen 2 gene as a potential hepatocellular carcinoma therapeutic target by hub gene screening with topological analysis. Liu J et al., 2019 Nov, Oncol LettRead this paper


